Global Oncology Biomarker Market Growth (Status and Outlook) 2025-2031

According to this study, the global Oncology Biomarker market size will reach US$ million by 2031.

A biomarker is referred to as a traceable biomolecule, whose presence found in body fluids such as blood, serum, urine, and tumor fluid that indicates disease or an underlying condition such as cancer.

United States market for Oncology Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Oncology Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Oncology Biomarker is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Oncology Biomarker players cover Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Genomic Health, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Oncology Biomarker Industry Forecast” looks at past sales and reviews total world Oncology Biomarker sales in 2024, providing a comprehensive analysis by region and market sector of projected Oncology Biomarker sales for 2025 through 2031. With Oncology Biomarker sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Biomarker industry.

This Insight Report provides a comprehensive analysis of the global Oncology Biomarker landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Oncology Biomarker portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oncology Biomarker market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Biomarker and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Biomarker.

This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Biomarker market by product type, application, key players and key regions and countries.

Segmentation by Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Segmentation by Application:
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
F.Hoffmann-La Roche Ltd.
Genomic Health
GlaxoSmithKline plc
Novartis AG
Merck & Co.
Pfizer
Qiagen N.V.

Please note: The report will take approximately 2 business days to prepare and deliver. Show more